NEW YORK, March 3 (Reuters) - Gilead Sciences ( GILD )

set aside $200 million for a potential settlement with federal

prosecutors to resolve an investigation into the drugmaker's

promotional speakers program for HIV drugs.

The Foster City, California-based company disclosed the

potential resolution with the Manhattan U.S. Attorney's office

in a Friday afternoon securities filing.

Gilead said it had received a subpoena in 2017, but did not

provide additional details about the probe in its filing.

The company, which first disclosed the probe in 2018, said

in a statement on Monday: "We have taken a litigation accrual

for a potential settlement."

A spokesman for the Manhattan U.S. Attorney's office

declined to comment.

Promotional speaker programs in which doctors are paid by

drugmakers to deliver lectures about their products have drawn

past Justice Department scrutiny.

In 2020, Swiss drugmaker Novartis paid more than

$600 million to settle with the Manhattan U.S. Attorney over

claims its speaker program was a cover for paying bribes to

doctors to prescribe its medication.

Novartis at the time said it was "committed to doing what is

right" and had established an enhanced compliance framework.

Gilead's HIV drug sales rose 16% to $5.45 billion in the

fourth quarter of 2024, contributing to a surge in its share

price.

The company expects to launch a new drug, lenacapavir, for

protecting against HIV infection later this year.